Since the publication with the February 2022 compounding possibility notify, FDA is now aware about expanding public curiosity in using sublingual and oral dosage forms of compounded ketamine to the procedure of psychiatric disorders. FDA understands that the ability to get hold of these solutions by means of telemedicine platforms https://ketalinic.com/ketamine-powder-nasal-spray-vials/